European Journal of Breast Health, 2022 Objective:Patients with triple-negative (TN) or human epidermal growth factor 2 (HER2)-enriched ipsilateral breast cancer recurrence (IBCR) seem to be excluded from a second breast-conserving surgery (BCS) under the assumption that salvage mastectomy ...
Damiano Gentile +8 more
doaj +1 more source
[Anti-HER2 vaccines: The HER2 immunotargeting future?].
Pathologie-biologie, 2009 Breast cancer is a widely spread women's disease. In spite of progress in the field of surgery and adjuvant therapies, the risk of breast cancer metastatic relapses remains high especially in those overexpressing HER2. Different studies have shown cellular and/or humoral immune responses against HER2 in patients with HER2-overexpressing tumors.
Ladjemi, Maha-Zohra +3 more
openaire +2 more sources
Epidemiological and pathological characteristics of postsurgical cases of invasive breast cancer among ethnicities of Iran in 2018: A single center cross-sectional study [PDF]
Archive of Oncology, 2020 Background: Present study aimed to investigate immunohistochemical parameters in post-surgical cases of invasive breast cancer. Methods: In this single center cross-sectional study we investigated ethnicity, familial history, type of cancer, stage of ...
Sayad Soheila +4 more
doaj
Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
Exploration of Targeted Anti-tumor Therapy, 2021 About 15–20% of all breast cancers (BCs) are defined human epidermal growth factor receptor 2 (HER2)-positive, based on the overexpression of HER2 protein and/or amplification of ERBB2 gene.
Paolo Tarantino +2 more
doaj +1 more source
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. [PDF]
, 2016 BackgroundHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer is a particularly aggressive form of the disease, and ultimately progresses in patients with metastases on standard therapies.
Cortes, Javier +10 more
core +2 more sources
陆军军医大学学报, 2022 Objective To analyze the efficacy and safety of different treatments in advanced lung adenocarcinoma patients with v-raf murine sarcoma viral oncogene homolog B1(BRAF) BRAF V600E mutation, human epidermal growth factor receptor 2 (HER2) mutation ...
LIN Qingyue, QU Jingjing, ZHOU Jianying
doaj +1 more source
Characterising the tumour morphological response to therapeutic intervention:an ex vivo model [PDF]
, 2012 In cancer, morphological assessment of histological tissue samples is a fundamental part of both diagnosis and prognosis. Image analysis offers opportunities to support that assessment through quantitative metrics of morphology.
Bown, James L. +6 more
core +5 more sources
Libyan Journal of Medicine, 2021 Aim: Colorectal cancer (CRC) is one of the leading cancers in the world. Even though its mortality and pathophysiology are well documented in the US and the European countries, it is seldom studied in North African population.
Eman A. Abdul Razzaq +9 more
doaj +1 more source
Regioselective and stoichiometrically controlled conjugation of photodynamic sensitizers to a HER2 targeting antibody fragment [PDF]
, 2014 The rapidly increasing interest in the synthesis of antibody–drug conjugates as powerful targeted anticancer agents demonstrates the growing appreciation of the power of antibodies and antibody fragments as highly selective targeting moieties.
Boyle, Ross W. +6 more
core +1 more source
Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. [PDF]
, 2013 Data characterizing demographics, treatment patterns, and clinical outcomes in black patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) are limited.
Abidoye, Oyewale O +8 more
core +1 more source